New Pharmaceutical Drugs Pipeline
Escozine® has shown promising results in helping patients to overcome many viral infections, including COVID-19 as well as eliminating multiple cancer cell lines in clinical trials and has shown to have quality of life enhancement capabilities that could be marketed as an independent drug.
| Product | Country | Indication | Pre-Clinical | Clinical Trials | Reg. Filing | Approval/RG |
| Escozine® | Dominican Republic | SARS-CoV-2 (COVID-19) | ||||
| Escozine® | United States | SARS-CoV-2 (COVID-19) | ||||
| Escozine® GNP-1 | United States | Pancreatic Cancer | ||||
| Escozine® GNP-1 | Dominican Republic | Pancreatic Cancer | ||||
| Escozine® GNP-1 | United States | Pancreatic Cancer |
OUR MEDICINAL DRUG DEVELOPMENT
Our goal is to research and develop, new generation of medicines that will benefit patients around the globe. Our passionate commitment is to innovate and reveal a new approach to drug development, that is safe and effective.
MedolifeRx provides solutions for the unmet needs of multiple important therapeutics. Areas include; Anti-Viral medicine, Oncology, Inflammation, Immunology, and targets rare diseases.
Escozine® has shown promising results, in proof-of-concept clinical studies for Covid-19 patients.
Once Escozine® receives IND approval, we will prepare for an NDA submission for Covid-19.
Pre-IND / NDA STRATEGY
Escozine®/ Covid-19: Data on Escozine® has been filed under pre-IND with US FDA as a potential COVID1-19. Clinical studies showing efficacy and safety of product
Escozine® GNP-1/ Pancreatic Cancer (Orphan Drug):
As a critical medicine for the Covid-19 Pandemic, we anticipate the approval of the product, in a shorter time period. Given that Scorpion Peptide is the main ingredient for Escozine/ Covid-19 and Escozine GNP-1, we strategize that the approval of the Escozine/Covid-19 drug can facilitate the fast tracking to the second phase of Escozine GNP-1/Pancreatic Cancer drug study.
Burbank Facility
FDA COMPLIANT FACILITY – New product development – Utilizing modern technologies like Nano machine and proprietary patented polarization technology machine, to develop advanced drugs and nutraceuticals. Cleanroom ISO 8/Class 100 000: